Jim Cramer on Royalty Pharma: "It's a Terrific Company"

Royalty Pharma plc (NASDAQ:RPRX) is one of the stocks Jim Cramer shared his take on. A caller asked for Cramer’s take on the stock, and here’s what he had to say:

Royalty just keeps going higher… I love that whole business where they help fund bio, and they get the returns. It’s a terrific company. I remember when GA brought it public, and I liked it then, I like it now.

Royalty Pharma plc (NASDAQ:RPRX) makes money by buying up royalties for multiple drugs and funding new research in the biotech world. Its current line-up includes a vast number of treatments from cancer to rare diseases. On January 11, the company announced that it had entered into a funding agreement with Teva Pharmaceuticals to accelerate the clinical development of TEV-‘408, an anti-IL-15 antibody targeting several autoimmune diseases. CEO and Chairman of the Board of Royalty Pharma plc (NASDAQ:RPRX), Pablo Legorreta, said:

Vitiligo is a chronic autoimmune skin disease that can have a profound emotional and psychosocial burden, yet current treatment options are insufficient. Our continued collaboration underscores Royalty Pharma’s role as a long-term, trusted partner with a focus on funding innovation in potentially transformative and practice changing therapies.

While we acknowledge the potential of RPRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.